Trial Profile

Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician's Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Olaparib (Primary) ; Capecitabine; Carboplatin; Cisplatin; Eribulin; Gemcitabine; Paclitaxel
Indications Advanced breast cancer; Brain metastases; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms SOLARA

11 Oct 2024 Planned End Date changed from 1 Sep 2026 to 1 Nov 2026.
11 Oct 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Nov 2025.
19 Sep 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com